Foundayo vs the Wegovy Tablet: How Do the New Oral GLP‑1 Weight-Loss Medicines Compare?
- AJ Hill Aesthetics
- 10 minutes ago
- 11 min read
For several years, the most effective prescription medicines for weight management have mainly been available as injections. This is beginning to change following the UK authorisation of two once-daily GLP‑1 tablets: Wegovy, containing oral semaglutide, and Foundayo, containing orforglipron.
The Medicines and Healthcare products Regulatory Agency (MHRA) authorised the Wegovy tablet on 11 June 2026. This was followed by the authorisation of Foundayo on 10 August 2026, making the UK the first country in Europe to approve orforglipron for weight management and type 2 diabetes.
Although both medicines act on the GLP‑1 receptor and are taken by mouth, they are not the same treatment. They contain different active ingredients, have different dosing instructions and were studied in separate clinical trials.
What is Foundayo?
Foundayo is the brand name for orforglipron, a prescription-only, once-daily GLP‑1 receptor agonist developed by Eli Lilly.
It has been authorised in the UK for weight loss and long-term weight management, alongside a reduced-calorie diet and increased physical activity, in adults who initially have:
A body mass index (BMI) of 30 kg/m² or above; or
A BMI between 27 and 30 kg/m² with at least one weight-related health condition.
Relevant health conditions may include high blood pressure, prediabetes, type 2 diabetes, abnormal blood fats, obstructive sleep apnoea, impaired heart function or established cardiovascular disease.
Foundayo has also been authorised to improve blood glucose control in adults with insufficiently controlled type 2 diabetes. However, prescribing for diabetes and prescribing for weight management are distinct clinical decisions.
The MHRA describes Foundayo as a prescription-only medicine that should only be supplied following an appropriate clinical assessment. It was not available through the NHS at the time of its UK authorisation, and any future NHS availability will depend on NICE assessment and local commissioning arrangements. MHRA: UK authorisation of Foundayo
How does Foundayo work?
Orforglipron activates the glucagon-like peptide-1, or GLP‑1, receptor. GLP‑1 is a hormone naturally released after eating and is involved in appetite regulation, digestion and blood glucose control.
By stimulating the GLP‑1 receptor, Foundayo can:
Reduce hunger;
Increase feelings of fullness after eating;
Reduce food cravings;
Help a person consume fewer calories; and
Improve glucose-dependent insulin secretion in people with type 2 diabetes.
Like other GLP‑1 medicines, Foundayo may also delay gastric emptying. This can contribute to fullness but may also contribute to gastrointestinal side effects.
Foundayo is intended to support, rather than replace, changes to diet, physical activity and other aspects of long-term weight management.
What makes Foundayo different from existing GLP‑1 medicines?
Most established GLP‑1 medicines, including injectable Wegovy and Mounjaro, are peptide-based medicines. Peptides can be broken down in the digestive system, which is one reason why many of these treatments have traditionally been administered by injection.
Orforglipron is different because it is a small-molecule, non-peptide GLP‑1 receptor agonist. Its chemical structure allows it to be absorbed as a conventional tablet without the strict fasting conditions required by oral semaglutide.
Foundayo can therefore be taken:
Once daily;
At any time of day;
With or without food; and
Without restrictions on water intake.
The tablet should be swallowed whole and should not be crushed, chewed or broken.
This flexibility may make Foundayo easier to fit around meals, shift work, other tablets and irregular daily routines. However, it still has to be remembered every day, whereas injectable Wegovy is administered once weekly.
How is Foundayo taken?
The authorised UK dose-escalation schedule begins at 0.8 mg once daily. The dose is increased gradually, with at least 30 days at each dose level:
Treatment stage | Foundayo dose |
Initial dose | 0.8 mg once daily |
First increase | 2.5 mg once daily |
Subsequent doses, if required | 5.5 mg, 9 mg, 14.5 mg and 17.2 mg once daily |
Maximum authorised dose | 17.2 mg once daily |
Not everyone will need to reach the maximum dose. Decisions about dose escalation should consider weight-management response, side effects, relevant medical conditions and the person’s ability to tolerate treatment.
The marketed tablet strengths differ numerically from the capsule doses used in the original ATTAIN‑1 clinical trial. This reflects a later tablet formulation; the milligram figures from the research capsules should therefore not be used as a self-dosing guide.
If a dose is forgotten, the UK patient leaflet advises taking it when remembered on the same day, without taking more than one tablet in a day. Patients should always follow the instructions supplied with their own prescription. Foundayo UK patient information leaflet
How effective was Foundayo in clinical trials?
The principal evidence for weight management comes from ATTAIN‑1, a Phase III randomised, double-blind, placebo-controlled trial involving 3,127 adults.
Participants had obesity, or were overweight with at least one weight-related condition, and did not have diabetes. Everyone received support with a healthy diet and physical activity.
Participants were assigned to orforglipron or placebo for 72 weeks.
At the highest trial dose:
Average weight reduction was 12.4% using an efficacy estimate that assumed participants remained on their assigned treatment without using another weight-management intervention.
Average weight reduction was 11.2% using the treatment-regimen estimate, which included results regardless of treatment discontinuation or the use of another intervention.
In the efficacy analysis, approximately 59.6% lost at least 10% of their starting weight.
Approximately 39.6% lost at least 15%.
In the broader treatment-regimen analysis, approximately 18.4% lost at least 20%.
For illustration, a 12.4% reduction would be approximately 12.4 kg for someone starting at 100 kg. It should not be interpreted as a prediction of an individual person’s result.
Improvements were also reported in waist circumference, systolic blood pressure, triglycerides and non-HDL cholesterol. These are encouraging cardiometabolic findings, but they do not by themselves prove that Foundayo prevents heart attacks, strokes or cardiovascular death.
The peer-reviewed ATTAIN‑1 report concluded that orforglipron produced significantly greater weight reduction than placebo, with an adverse-effect profile consistent with the GLP‑1 medicine class. ATTAIN‑1 publication and Eli Lilly ATTAIN‑1 results
What is the Wegovy oral tablet?
The Wegovy tablet is a once-daily weight-management medicine containing semaglutide. It contains the same active ingredient as the Wegovy injection, but the oral and injectable products have different doses, administration instructions and formulations.
Oral Wegovy was authorised by the MHRA on 11 June 2026 for adults with:
A BMI of 30 kg/m² or above; or
A BMI between 27 and 30 kg/m² with at least one weight-related condition.
It is used alongside a reduced-calorie meal plan and increased physical activity.
The Wegovy tablet should not be confused with Rybelsus. Although Rybelsus also contains oral semaglutide, it is a separate product with different authorised indications and doses.
How must the Wegovy tablet be taken?
Oral semaglutide is a peptide medicine and its absorption is sensitive to food, fluid and other medicines in the stomach.
The Wegovy tablet must therefore be taken:
After fasting for at least eight hours;
On an empty stomach;
With a small sip of water, up to 120 ml;
Without splitting, crushing or chewing the tablet; and
At least 30 minutes before eating, drinking or taking any other oral medicine.
Eating or drinking too soon after taking the tablet can reduce semaglutide absorption and may affect treatment response.
The UK dose schedule is:
Treatment month | Wegovy tablet dose |
Month 1 | 1.5 mg once daily |
Month 2 | 4 mg once daily |
Month 3 | 9 mg once daily |
Month 4 onwards | 25 mg once daily |
The MHRA also states that a person already receiving private treatment with the 2.4 mg weekly Wegovy injection may be transitioned directly to the 25 mg daily tablet, but this must be a clinician-led decision. Patients should not switch products or doses themselves. MHRA: approval of the Wegovy tablet and Wegovy tablet patient leaflet
How effective was the Wegovy tablet?
The main evidence comes from OASIS‑4, a Phase III trial involving 307 adults with obesity, or overweight with at least one weight-related condition, who did not have diabetes.
Participants received oral semaglutide 25 mg or placebo alongside lifestyle intervention for 64 weeks.
At 64 weeks:
Average weight reduction was 16.6% in the analysis estimating the effect if participants remained on treatment.
The broader treatment-policy estimate was 13.6%, compared with approximately 2.4% for placebo.
Around one-third of participants receiving oral semaglutide lost at least 20% of their starting body weight in the on-treatment analysis.
These results suggest that the Wegovy tablet can produce substantial weight reduction when taken consistently and according to its fasting instructions. OASIS‑4 publication
Foundayo compared with the Wegovy tablet
Feature | Foundayo | Wegovy tablet |
Active ingredient | Orforglipron | Semaglutide |
Manufacturer | Eli Lilly | Novo Nordisk |
Medicine type | Small-molecule, non-peptide GLP‑1 agonist | Peptide GLP‑1 agonist |
Frequency | Once daily | Once daily |
Food restrictions | None | Must be taken after an eight-hour fast |
Water restrictions | None specified | Up to 120 ml when taking the tablet |
Wait before food, drink or other tablets | No | At least 30 minutes |
Starting dose | 0.8 mg daily | 1.5 mg daily |
Maximum UK dose | 17.2 mg daily | 25 mg daily |
Main obesity trial | ATTAIN‑1 | OASIS‑4 |
Trial duration | 72 weeks | 64 weeks |
On-treatment average weight reduction | 12.4% | 16.6% |
Broader treatment estimate | 11.2% | 13.6% |
Refrigeration | Not required | Not required |
UK approval | 10 August 2026 | 11 June 2026 |
Does oral Wegovy cause more weight loss than Foundayo?
The available trial figures appear to favour oral Wegovy, but they do not prove that it is superior for an individual patient.
ATTAIN‑1 and OASIS‑4 were separate trials. They differed in participant numbers, treatment duration, study procedures, discontinuation patterns and potentially other characteristics.
Comparing 12.4% with 16.6% is therefore an indirect, cross-trial comparison rather than the result of a randomised head-to-head study.
A fair interpretation is that:
Both medicines produced clinically meaningful average weight loss;
Oral Wegovy produced the larger average reduction in its own pivotal trial;
Foundayo offers substantially simpler administration;
Adherence to oral Wegovy’s fasting routine may influence its effectiveness;
Side effects and discontinuation may affect the results achieved in routine practice; and
There is currently insufficient direct evidence to state that one tablet will be more effective for every patient.
The most effective treatment in practice may be the one that is clinically appropriate, tolerated and taken consistently.
Side effects of Foundayo and oral Wegovy
The side-effect profiles overlap because both medicines stimulate the GLP‑1 receptor. Very common effects include:
Nausea;
Vomiting;
Diarrhoea;
Constipation;
Abdominal discomfort or pain; and
Indigestion.
Other possible effects include bloating, reflux, burping, flatulence, headache, tiredness, dizziness, gallstones and hair loss. Hair loss during pharmacological weight management may also be influenced by rapid weight reduction, insufficient protein or micronutrient intake and other health factors.
In ATTAIN‑1, gastrointestinal effects were generally mild to moderate but were common. At the highest trial dose, reported events included nausea in approximately 33.7%, constipation in 25.4%, diarrhoea in 23.1% and vomiting in 24%. Around 10.3% discontinued the highest dose because of adverse events.
These rates should not be directly compared with rates from a different trial as proof that one medicine is better tolerated.
Gradual dose escalation is used with both medicines to improve tolerability. Increasing a dose faster than prescribed may increase the likelihood or severity of gastrointestinal symptoms.
Important safety considerations
Foundayo and the Wegovy tablet are not suitable for everyone. A prescriber should assess the person’s medical history, current medicines, weight-related conditions, previous treatment, pregnancy plans and ability to follow the treatment safely.
Particular consideration is required for people with:
Current or previous pancreatitis;
Gallstones or gallbladder disease;
Severe gastrointestinal disease or gastroparesis;
Kidney problems or a risk of dehydration;
Diabetes treated with insulin or a sulfonylurea;
Diabetic retinopathy or new visual symptoms;
Planned surgery or procedures involving anaesthesia; or
A history suggesting disordered eating or an eating disorder.
Severe, persistent abdominal pain, particularly if it radiates to the back or occurs with vomiting, requires urgent medical assessment because it may indicate acute pancreatitis.
Severe constipation accompanied by significant abdominal pain, swelling, vomiting or an inability to pass stool or wind also requires urgent assessment.
Sudden loss of vision or rapidly worsening eyesight must be assessed urgently.
Both medicines can increase the risk of hypoglycaemia when combined with insulin or a sulfonylurea, although GLP‑1 treatment used by itself has a relatively low risk of causing clinically significant low blood glucose.
Pregnancy and contraception
Neither Foundayo nor the Wegovy tablet should be used during pregnancy or breastfeeding.
The UK Foundayo leaflet advises stopping orforglipron at least three weeks before a planned pregnancy. It also warns that orforglipron may reduce the effectiveness of oral hormonal contraception. A barrier method or non-oral contraception should be considered for 30 days after starting treatment and for 30 days after each dose increase.
The Wegovy tablet should be stopped at least two months before a planned pregnancy.
Anyone who becomes pregnant while taking either medicine should contact their prescriber promptly.
Medicine interactions
Foundayo’s small-molecule structure creates some interaction considerations that differ from semaglutide. Its UK leaflet identifies medicines that may increase or reduce orforglipron concentrations, including certain antibiotics, antifungals, antiviral medicines, anti-seizure medicines, rifampicin and St John’s wort. It may also affect exposure to medicines including simvastatin, rosuvastatin and topotecan.
For oral Wegovy, particular attention may be required with levothyroxine and oral anticoagulants such as warfarin. Its strict administration routine can also affect the timing of other morning medicines.
A complete and accurate medication history, including prescribed medicines, over-the-counter products and herbal remedies, is therefore essential before either treatment is prescribed.
What are Foundayo’s main advantages?
Potential advantages include:
No injections;
No refrigeration;
No fasting requirement;
No need to delay food, drink or other tablets;
Flexible administration at any time of day;
Clinically meaningful average weight loss; and
Authorisation for both weight management and insufficiently controlled type 2 diabetes.
These features may be particularly helpful for people who dislike needles or find oral Wegovy’s fasting routine difficult.
What are its limitations?
Potential disadvantages include:
The need to remember a tablet every day;
Average trial weight loss that was lower than that reported with oral Wegovy in a separate study;
Common gastrointestinal side effects;
A longer escalation pathway through several tablet strengths;
Important interactions with some medicines;
Specific contraceptive precautions;
Limited long-term real-world experience because it is newly authorised; and
No established UK NHS availability at the time of approval.
Foundayo also does not yet have the same length of clinical experience as semaglutide. Ongoing post-authorisation monitoring will be important for identifying uncommon or longer-term adverse effects.
Which tablet is the better option?
There is no single oral GLP‑1 medicine that will be best for everyone.
Oral Wegovy may appeal to someone who prioritises the larger average weight reduction observed in its pivotal trial and who can reliably follow the fasting instructions.
Foundayo may appeal to someone who wants a tablet without food, water or timing restrictions.
Its simpler administration could support better adherence for some people, even though its average trial weight reduction was lower.
The choice should also account for:
Medical history and contraindications;
Other medicines;
Diabetes status;
Pregnancy plans and contraception;
Previous response to GLP‑1 treatment;
Side-effect tolerance;
Daily routine;
Treatment cost and continuity of supply; and
The person’s preferences and weight-management goals.
Neither medicine should be selected solely on the basis of an advertised percentage.
The bottom line
Foundayo represents an important development in weight-management treatment. It is the first authorised UK weight-loss tablet to use orforglipron, a non-peptide, small-molecule GLP‑1 receptor agonist that can be taken without fasting or food restrictions.
In ATTAIN‑1, the highest trial dose produced an average weight reduction of 12.4% among participants assumed to remain on treatment, or 11.2% when treatment discontinuation and other interventions were included.
The Wegovy tablet produced a larger average reduction in its separate OASIS‑4 trial—16.6% while remaining on treatment or 13.6% under the broader analysis—but requires careful fasting and administration.
These studies were not a head-to-head comparison. Foundayo may offer greater convenience, whereas oral Wegovy currently has the stronger headline weight-loss result. Safety, adherence, interactions, individual clinical circumstances and patient preference are likely to be more important than trial averages when choosing between them.
Both medicines are prescription-only treatments requiring a proper clinical assessment, ongoing monitoring and support with nutrition, physical activity and sustainable behaviour change. They should only be obtained from a registered pharmacy following a valid prescription.
Weight loss is a journey that requires support, patience, and the right tools. Foundayo may be one of those tools that helps you move closer to your health goals.
If you'd like to discuss Foundayo, or other treatment options, please drop us an email at info@ajhillaesthetics.co.uk
Disclaimer: This post is for informational purposes only and does not replace professional medical advice. Always consult a healthcare professional before starting any new medication or treatment.
